Hans-Georg Wirsching
Hans-Georg Wirsching
University Hospital and University of Zurich
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
F Sahm, D Schrimpf, D Stichel, DTW Jones, T Hielscher, S Schefzyk, ...
The lancet oncology 18 (5), 682-694, 2017
Advances in the molecular genetics of gliomas—implications for classification and therapy
G Reifenberger, HG Wirsching, CB Knobbe-Thomsen, M Weller
Nature reviews Clinical oncology 14 (7), 434-452, 2017
HG Wirsching, M Weller
Malignant Brain Tumors: State-of-the-Art Treatment, 265-288, 2017
MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial
M Weller, G Tabatabai, B Kästner, J Felsberg, JP Steinbach, A Wick, ...
Clinical cancer research 21 (9), 2057-2064, 2015
Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial
B Suchorska, M Weller, G Tabatabai, C Senft, P Hau, MC Sabel, ...
Neuro-oncology 18 (4), 549-556, 2016
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
P Sievers, T Hielscher, D Schrimpf, D Stichel, DE Reuss, AS Berghoff, ...
Acta neuropathologica 140, 409-413, 2020
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence
LM Katz, T Hielscher, B Liechty, J Silverman, D Zagzag, R Sen, P Wu, ...
Acta neuropathologica 135, 955-963, 2018
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery
PJ Cimino, M Zager, L McFerrin, HG Wirsching, H Bolouri, B Hentschel, ...
Acta neuropathologica communications 5 (1), 1-14, 2017
Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated
SLN Maas, D Stichel, T Hielscher, P Sievers, AS Berghoff, D Schrimpf, ...
Journal of clinical oncology 39 (34), 3839-3852, 2021
Predicting outcome of epilepsy after meningioma resection
HG Wirsching, C Morel, C Gmür, MC Neidert, CR Baumann, A Valavanis, ...
Neuro-oncology 18 (7), 1002-1010, 2016
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
HG Wirsching, G Tabatabai, U Roelcke, AF Hottinger, F Jörger, A Schmid, ...
Annals of oncology 29 (6), 1423-1430, 2018
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
N Paramasivam, D Hübschmann, UH Toprak, N Ishaque, M Neidert, ...
Acta neuropathologica 138, 295-308, 2019
Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma
HG Wirsching, S Krishnan, AM Florea, K Frei, N Krayenbühl, ...
Brain 137 (2), 433-448, 2014
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma
PJ Cimino, Y Kim, HJ Wu, J Alexander, HG Wirsching, F Szulzewsky, ...
Genes & development 32 (7-8), 512-523, 2018
The role of molecular diagnostics in the management of patients with gliomas
HG Wirsching, M Weller
Current treatment options in oncology 17, 1-16, 2016
Anti–PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma
CI Ene, SA Kreuser, M Jung, H Zhang, S Arora, K White Moyes, ...
Neuro-oncology 22 (5), 639-651, 2020
Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma
RA Yoda, T Marxen, L Longo, C Ene, HG Wirsching, CD Keene, ...
Journal of Neuropathology & Experimental Neurology 78 (11), 1002-1010, 2019
Copy number profiling across glioblastoma populations has implications for clinical trial design
PJ Cimino, L McFerrin, HG Wirsching, S Arora, H Bolouri, R Rabadan, ...
Neuro-oncology 20 (10), 1368-1373, 2018
Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling
PJ Cimino, L Huang, L Du, Y Wu, J Bishop, J Dalsing-Hernandez, ...
Biomedical reports 10 (4), 218-224, 2019
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma
HG Wirsching, H Zhang, F Szulzewsky, S Arora, P Grandi, PJ Cimino, ...
JCI insight 4 (13), 2019
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20